PLRX
PLIANT THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.86
−0.13%Oct 19, 2026, 20:05 UTC
PLIANT THERAPEUTICS, INC. announced that a presentation on its ongoing FORTIFY Phase 1b trial of PLN-101095 is scheduled for the ESMO Congress 2026 in Madrid from October 23 to 27, 2026.
Source:Aug 11, 2026, 20:05 UTC
Pliant Therapeutics appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D. as seasoned oncology drug development leaders.
Source:Jul 13, 2026, 12:30 UTC
Pliant Therapeutics appointed Flavia Borellini and Robert Iannone to its board of directors.
Source: